Dolutegravir/lamivudine, sold under the brand name Dovato, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. It contains dolutegravir, an integrase inhibitor, and lamivudine, a reverse-transcriptase inhibitor. It is taken by mouth. Dolutegravir stops the activity of an enzyme called integrase (and is known as an integrase inhibitor), while lamivudine stops the activity of another enzyme called reverse transcriptase (and is known as a nucleoside reverse transcriptase inhibitor or NRTI).